267 related articles for article (PubMed ID: 30157114)
1. LONG-TERM VISUAL OUTCOMES AND CLINICAL FEATURES AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTION-RELATED ENDOPHTHALMITIS.
Rayess N; Obeid A; Storey PP; Juliano J; Rahimy E; Moshfeghi AA; Garg S; Hsu J
Retina; 2019 Nov; 39(11):2070-2076. PubMed ID: 30157114
[TBL] [Abstract][Full Text] [Related]
2. Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes.
Xu K; Chin EK; Bennett SR; Williams DF; Ryan EH; Dev S; Mittra RA; Quiram PA; Davies JB; Parke DW; Johnson JB; Cantrill HL; Almeida DRP
Ophthalmology; 2018 Aug; 125(8):1279-1286. PubMed ID: 29477689
[TBL] [Abstract][Full Text] [Related]
3. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
[TBL] [Abstract][Full Text] [Related]
4. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center.
Moshfeghi AA; Rosenfeld PJ; Flynn HW; Schwartz SG; Davis JL; Murray TG; Smiddy WE; Berrocal AM; Dubovy SR; Lee WH; Albini TA; Lalwani GA; Kovach JL; Puliafito CA
Retina; 2011 Apr; 31(4):662-8. PubMed ID: 21836400
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab.
Storey PP; Tauqeer Z; Yonekawa Y; Todorich B; Wolfe JD; Shah SP; Shah AR; Koto T; Abbey AM; Morizane Y; Sharma P; Wood EH; Morizane-Hosokawa M; Pendri P; Pancholy M; Harkey S; Jeng-Miller KW; Obeid A; Borkar DS; Chen E; Williams P; Okada AA; Inoue M; Shiraga F; Hirakata A; Shah CP; Prenner J; Garg S;
Am J Ophthalmol; 2019 Mar; 199():200-208. PubMed ID: 30552891
[TBL] [Abstract][Full Text] [Related]
6. Management and Visual Outcomes of Acute Bacterial Endophthalmitis Following Intravitreal Injection of Contaminated Bevacizumab in a Single Day.
Xu K; Mousa R; Loewenstein A; Barak A; Chin EK; Almeida DRP
Ophthalmic Surg Lasers Imaging Retina; 2020 Jun; 51(6):346-352. PubMed ID: 32579693
[TBL] [Abstract][Full Text] [Related]
7. Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia.
Al-Rashaed S; Alsulaiman SM; Alrushood AA; Almasaud J; Arevalo JF
Middle East Afr J Ophthalmol; 2016; 23(1):60-3. PubMed ID: 26957840
[TBL] [Abstract][Full Text] [Related]
8. Pars plana vitrectomy in the management of patients diagnosed with endophthalmitis following intravitreal anti-vascular endothelial growth factor injection.
Chaudhary KM; Romero JM; Ezon I; Fastenberg DM; Deramo VA
Retina; 2013; 33(7):1407-16. PubMed ID: 23492945
[TBL] [Abstract][Full Text] [Related]
9. Changes in Management Based on Vitreous Culture in Endophthalmitis After Intravitreal Anti-vascular Endothelial Growth Factor Injection.
Patel SN; Storey PP; Pancholy M; Obeid A; Wibbelsman TD; Levin H; Hsu J; Garg SJ; Dunn JP; Vander JF
Am J Ophthalmol; 2019 Nov; 207():224-231. PubMed ID: 31201794
[TBL] [Abstract][Full Text] [Related]
10. MICROBIAL SPECTRUM AND OUTCOMES OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION VERSUS PARS PLANA VITRECTOMY.
Garg SJ; Dollin M; Storey P; Pitcher JD; Fang-Yen NH; Vander J; Hsu J;
Retina; 2016 Feb; 36(2):351-9. PubMed ID: 26200514
[TBL] [Abstract][Full Text] [Related]
11. COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB.
Bavinger JC; Yu Y; VanderBeek BL
Retina; 2019 Oct; 39(10):2004-2011. PubMed ID: 30312260
[TBL] [Abstract][Full Text] [Related]
12. Endophthalmitis following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: Changes in Incidence and Outcomes over a 9-Year Period.
Pancholy M; Storey PP; Levin HJ; Obeid A; Patel SN; Kuley B; Hsu J; Spirn MJ; Fineman M; Klufas MA; Gupta O; Ho AC; Garg SJ
Curr Eye Res; 2021 Sep; 46(9):1370-1377. PubMed ID: 33522314
[No Abstract] [Full Text] [Related]
13. Early intravitreal treatment of endogenous bacterial endophthalmitis.
Yonekawa Y; Chan RV; Reddy AK; Pieroni CG; Lee TC; Lee S
Clin Exp Ophthalmol; 2011 Nov; 39(8):771-8. PubMed ID: 22050564
[TBL] [Abstract][Full Text] [Related]
14. Endophthalmitis after Anti-VEGF Intravitreal Injections with Aqueous Chlorhexidine versus Povidone-Iodine as Ocular Antiseptics.
Ton NS; Goncharov V; Zapata I; Adam MK
Ophthalmol Retina; 2024 Jun; 8(6):521-526. PubMed ID: 38122867
[TBL] [Abstract][Full Text] [Related]
15. Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.
Daien V; Nguyen V; Essex RW; Morlet N; Barthelmes D; Gillies MC;
Ophthalmology; 2018 Jan; 125(1):66-74. PubMed ID: 28801117
[TBL] [Abstract][Full Text] [Related]
16. Lid splinting eyelid retraction technique: a minimised sterile approach for intravitreal injections.
Munro M; Williams GR; Ells A; Fielden M; Kherani A; Mitchell P; Ruzicki J; Adatia FA
Br J Ophthalmol; 2018 Sep; 102(9):1254-1258. PubMed ID: 29246893
[TBL] [Abstract][Full Text] [Related]
17. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates.
Englander M; Chen TC; Paschalis EI; Miller JW; Kim IK
Br J Ophthalmol; 2013 Apr; 97(4):460-5. PubMed ID: 23390167
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor.
Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ
Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037
[TBL] [Abstract][Full Text] [Related]
20. Acute-onset endophthalmitis after clear corneal cataract surgery (1996-2005). Clinical features, causative organisms, and visual acuity outcomes.
Lalwani GA; Flynn HW; Scott IU; Quinn CM; Berrocal AM; Davis JL; Murray TG; Smiddy WE; Miller D
Ophthalmology; 2008 Mar; 115(3):473-6. PubMed ID: 18067969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
